[go: up one dir, main page]

FR3111917B1 - Signature moléculaire d’un état alopécique commun, associée aux jonctions cellulaires - Google Patents

Signature moléculaire d’un état alopécique commun, associée aux jonctions cellulaires Download PDF

Info

Publication number
FR3111917B1
FR3111917B1 FR2006900A FR2006900A FR3111917B1 FR 3111917 B1 FR3111917 B1 FR 3111917B1 FR 2006900 A FR2006900 A FR 2006900A FR 2006900 A FR2006900 A FR 2006900A FR 3111917 B1 FR3111917 B1 FR 3111917B1
Authority
FR
France
Prior art keywords
alopecic
common
condition
area
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2006900A
Other languages
English (en)
Other versions
FR3111917A1 (fr
Inventor
Yann Mahe
Khalid Bakkar
Samra Elias Bou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Priority to FR2006900A priority Critical patent/FR3111917B1/fr
Priority to PCT/EP2021/068037 priority patent/WO2022003041A1/fr
Priority to CN202180046092.5A priority patent/CN115997036A/zh
Priority to EP21734871.3A priority patent/EP4172368A1/fr
Priority to US18/002,270 priority patent/US20230265511A1/en
Publication of FR3111917A1 publication Critical patent/FR3111917A1/fr
Application granted granted Critical
Publication of FR3111917B1 publication Critical patent/FR3111917B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Signature moléculaire d’un état alopécique commun, associée au aux jonctions cellulaires La présente invention concerne une méthode de pronostic et/ou de diagnostic in vitro d’un état alopécique commun du cuir chevelu chez un sujet, notamment l’alopécie androgénétique, comprenant au moins une étape a) de mesure du niveau d’expression, dans un échantillon biologique issu d’une zone suspectée d’être une zone alopécique ou de devenir une zone alopécique chez ledit sujet, d’au moins un gène choisi parmi CDH1, ACTB, ACTBL2, TUBB, TUBB2A, GSN, MYO3B, MYO5B, MYO6, DSG2, DSG3, DSG4, DSC2, GJB2, GJA1, GJB6, GJA3, TJP2, CLDN8, CLDN10, CLDN19, et éventuellement d’au moins un gène choisi parmi CTNNB1 et CTNND2. L’invention concerne également une méthode in vitro d’évaluation de l’efficacité d’un traitement d’un état alopécique commun, une méthode de traitement cosmétique, l’utilisation de modulateur dudit ou desdits gènes précités, ainsi qu’une méthode d’identification d’un composé permettant la prévention et/ou le traitement d’un état alopécique commun.
FR2006900A 2020-06-30 2020-06-30 Signature moléculaire d’un état alopécique commun, associée aux jonctions cellulaires Active FR3111917B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR2006900A FR3111917B1 (fr) 2020-06-30 2020-06-30 Signature moléculaire d’un état alopécique commun, associée aux jonctions cellulaires
PCT/EP2021/068037 WO2022003041A1 (fr) 2020-06-30 2021-06-30 Signature moléculaire d'un état alopécique commun, associé aux jonctions cellulaires
CN202180046092.5A CN115997036A (zh) 2020-06-30 2021-06-30 与细胞连接相关的普通秃发状态的分子特征
EP21734871.3A EP4172368A1 (fr) 2020-06-30 2021-06-30 Signature moléculaire d'un état alopécique commun, associé aux jonctions cellulaires
US18/002,270 US20230265511A1 (en) 2020-06-30 2021-06-30 Molecular signature of a common alopecic state, associated with cell junctions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2006900A FR3111917B1 (fr) 2020-06-30 2020-06-30 Signature moléculaire d’un état alopécique commun, associée aux jonctions cellulaires
FR2006900 2020-06-30

Publications (2)

Publication Number Publication Date
FR3111917A1 FR3111917A1 (fr) 2021-12-31
FR3111917B1 true FR3111917B1 (fr) 2025-04-11

Family

ID=74045473

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2006900A Active FR3111917B1 (fr) 2020-06-30 2020-06-30 Signature moléculaire d’un état alopécique commun, associée aux jonctions cellulaires

Country Status (5)

Country Link
US (1) US20230265511A1 (fr)
EP (1) EP4172368A1 (fr)
CN (1) CN115997036A (fr)
FR (1) FR3111917B1 (fr)
WO (1) WO2022003041A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3143040A1 (fr) * 2022-12-12 2024-06-14 L'oreal Méthode de pronostic et/ou de diagnostic d’une perte de densité capillaire

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2854243A1 (fr) * 2003-04-24 2004-10-29 Oreal Procede de determination d'etats pre-alopeciques et/ou d'atteintes cutanees au moyen d'un marqueur predictif: hif-1(hypoxia inducible factor-1)
CA2743473C (fr) * 2008-11-17 2022-06-14 Veracyte, Inc. Procedes et compositions de profilage moleculaire pour le diagnostic de maladies
US9198911B2 (en) * 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
CN104334191A (zh) * 2012-03-29 2015-02-04 纽约市哥伦比亚大学托管会 治疗毛发脱落疾病的方法
CN105188767A (zh) * 2012-07-25 2015-12-23 布罗德研究所有限公司 可诱导的dna结合蛋白和基因组干扰工具及其应用
US20190072541A1 (en) * 2015-08-14 2019-03-07 The Trustees Of Columbia University In The City Of New York Biomarkers for treatment of alopecia areata

Also Published As

Publication number Publication date
CN115997036A (zh) 2023-04-21
FR3111917A1 (fr) 2021-12-31
WO2022003041A1 (fr) 2022-01-06
US20230265511A1 (en) 2023-08-24
EP4172368A1 (fr) 2023-05-03

Similar Documents

Publication Publication Date Title
Wilke et al. Diagnosis of haploidy and triploidy based on measurement of gene copy number by real‐time PCR
Ahmed et al. Clonal expansions and loss of receptor diversity in the naive CD8 T cell repertoire of aged mice
Domingues et al. Proposal for a new risk stratification classification for meningioma based on patient age, WHO tumor grade, size, localization, and karyotype
Stephen et al. Dystonia
US20150218656A1 (en) Methods for detection and diagnosis of a lymphoid malignancy using high throughput sequencing
Thiffault et al. Diversity of ARSACS mutations in French-Canadians
Norris et al. Oligoclonal expansion of intraepidermal T cells in psoriasis skin lesions
Starnoni et al. Returning to work after multimodal treatment in glioblastoma patients
DE02782887T1 (de) Methoden und kompositionen, antikörper behandlung zu bewerten
CN1739030A (zh) 癌症细胞侵入的诊断和预防
FR3111917B1 (fr) Signature moléculaire d’un état alopécique commun, associée aux jonctions cellulaires
Rossi et al. Optimal time-points for minimal residual disease monitoring change on the basis of the method used in patients with acute myeloid leukemia who underwent allogeneic stem cell transplantation: a comparison between multiparameter flow cytometry and Wilms’ tumor 1 expression
CN108449997A (zh) 用于治疗斑秃的生物标志物
US20210003560A1 (en) Identification method for dermal sheath cup cells (dscc), and method for evaluating composition for hair follicle regeneration
Ferris et al. Noninvasive analysis of high-risk driver mutations and gene expression profiles in primary cutaneous melanoma
CN109680062A (zh) 一种检测微小残留病mrd的方法
Currier et al. Spectratype/immunoscope analysis of the expressed TCR repertoire
Shah et al. Parkinson’s Disease and its dermatological associations: is your skin whispering you a diagnosis?
Roberts et al. Mitochondrial DNA amplification success rate as a function of hair morphology
US20210238659A1 (en) Intraoral examination method using information on bacterial group related to clinical indexes
Saade et al. Updates on mechanisms of disease progression in precursor myeloma: Monoclonal gammopathy of undermined significance and smoldering myeloma
Holt et al. Association of hepsin gene variants with prostate cancer risk and prognosis
EP3722444A1 (fr) Procédé de détermination de sous-types rcc
WO2018204377A3 (fr) Tumeur opposée à du cfarn normal apparié
Siekierka‐Harreis et al. Impact of genetic polymorphisms of the renin–angiotensin system and of non‐genetic factors on kidney transplant function–a single‐center experience

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20211231

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6